In Brazil, epizootics among New World monkey species may indicate circulation of yellow fever (YF) virus and provide early warning of risk to humans. Between 1999 and 2001, the southern Brazilian state of Rio Grande do Sul initiated surveillance for epizootics of YF in non-human primates to inform vaccination of human populations. Following a YF outbreak, we analyzed epizootic surveillance data and assessed YF vaccine coverage, timeliness of implementation of vaccination in unvaccinated human populations. From October 2008 through June 2009, circulation of YF virus was confirmed in 67 municipalities in Rio Grande do Sul State; vaccination was recommended in 23 (34%) prior to the outbreak and in 16 (24%) within two weeks of first epizootic report. In 28 (42%) municipalities, vaccination began more than two weeks after first epizootic report. Eleven (52%) of 21 laboratory-confirmed human YF cases occurred in two municipalities with delayed vaccination. By 2010, municipalities with confirmed YF epizootics reported higher vaccine coverage than other municipalities that began vaccination. In unvaccinated human populations timely response to epizootic events is critical to prevent human yellow fever cases.
Yellow fever (YF) is a viral hemorrhagic disease that affects humans as well as several species of non-human primates, especially New World monkeys found in South America. Yellow fever virus (YFV) is maintained in a natural cycle involving tree-hole breeding mosquitoes and non-human primates hosts. Because YF is often fatal in susceptible New World monkey populations, sudden die-offs of New World monkeys or epizootics can signal YFV circulation in an environment where humans may be exposed. Surveillance for such events is an important tool to prevent human disease. The state of Rio Grande do Sul in southern Brazil was one of the first states to conduct passive and active surveillance for yellow fever virus circulation in non-human primates. During a rapidly-spreading YF outbreak in 2008–2009, surveillance for epizootics involving non-human primates informed vaccination of human populations in areas previously free of YF. In this study, we analyzed surveillance data to evaluate vaccine coverage, timeliness of notification, investigation and confirmation of epizootic events in relation to occurrence of human cases of YF. Epizootic surveillance is useful for directing the efforts of vaccine distribution. Prevention of YF in susceptible human populations requires immediate risk communication and implementation of vaccine recommendations after the first reports of epizootic activity when YF is suspected.
Citation: Almeida MAB, Cardoso JdC, dos Santos E, da Fonseca DF, Cruz LL, et al. (2014) Surveillance for Yellow Fever Virus in Non-Human Primates in Southern Brazil, 2001–2011: A Tool for Prioritizing Human Populations for Vaccination. PLoS Negl Trop Dis 8(3): e2741. doi:10.1371/journal.pntd.0002741
Editor: Duane J. Gubler, Duke-NUS, Singapore
Received: June 3, 2013; Accepted: February 3, 2014; Published: March 13, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Yellow fever surveillance activities were funded by the Rio Grande do Sul State Health Department and the Brazilian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Yellow fever (YF) is a disease caused by yellow fever virus (YFV), a member of the Flaviviridae family. The disease is considered endemic in parts of Africa and South America. Due to its varied clinical presentation and limited surveillance, yellow fever is under-reported: annually, approximately 5,000 cases are reported to WHO (World Health Organization) from Africa and 300 cases from South America but true incidence is believed to be 10–50 fold higher . The natural transmission cycle of YF involves tree-hole breeding mosquitoes and a wide array of monkeys, apes and marmosets . While primate species in Africa rarely develop fatal disease following YFV infection , several species of New World monkeys in the Americas are susceptible to severe, fatal YF disease. In the Americas, deaths of susceptible non-human primates are sentinel events that may indicate presence of YFV in a specific geographic location or environment and surveillance for such events is an important tool to prevent human disease . The goal of surveillance for deaths among non-human primates is to provide an early warning of risk of YFV transmission to humans, for rapid implementation of vaccination and prevention strategies. However, there have been few reports on how epizootic surveillance has been used to inform YF vaccination in human populations.
In Brazil, YF caused major urban epidemics and was considered a public health scourge in Brazilian cities until successful vector control and human vaccination strategies eliminated urban transmission in 1942 . However, the existence of a sylvatic cycle of YFV transmission involving non-human primates was described in the 1930s . Since that time, sporadic human cases and outbreaks have resulted from human activity in endemic areas and expansion of viral transmission to previously unaffected regions. The coastal area of Brazil is generally considered free of YF, including states on the northern, southeastern and southern coasts . Mainly in rural areas, the sylvatic cycle has been maintained by transmission among non-human primates and mosquito vectors. Some New World monkeys, e.g. howler monkeys (genus Alouatta) are extremely susceptible to YFV  and develop fatal disease, similar to humans . There are records of epizootics characterized by substantial mortality in howler monkeys populations due to this disease –.
Surveillance for YF detection in non-human primates was initiated in the state of Rio Grande do Sul, Brazil in 1999, initially as a passive strategy. Active surveillance began in 2001 following detection of YFV in the northwestern part of the state (bordering Argentina) , ,  and vaccination of residents in surrounding municipalities. Between December, 2002 and September, 2008, no evidence was found of YFV circulation or of immunity to YFV in blood specimens from more than 200 captured howler monkeys of Alouatta species or evidence of YFV in more than 2,000 mosquitoes (including Haemagogus leucocelaenus) . Seven years after active surveillance began, a rapidly-spreading YF outbreak in the state between October, 2008 and June, 2009 , . The coincident YF epizootic in non-human primates was the largest ever documented, with more than two-thirds of specimens from non-human primates testing positive for YFV infection , .
The YF outbreak provided the opportunity to evaluate surveillance for epizootic events involving deaths of non-human primates. We assessed timeliness of notification of non-human primate deaths in relation to the occurrence of confirmed human cases, vaccine coverage and timing of YF vaccination in municipalities in the state of Rio Grande do Sul during the YF outbreak.
This study involved analysis of routinely collected surveillance data and did not require ethical review according to the Brazilian National Committee for Ethics in Research.
Personally identifiable information was available only to surveillance officers and was not used in this study.
The state of Rio Grande do Sul is the southernmost state in Brazil, bordering Uruguay to the south and Argentina to the west (Figure 1). It occupies an area of 268,782 km2 and has 10,695,532 inhabitants . The state is divided in 496 municipalities, and the capital is Porto Alegre (1,409,939 inhabitants).
The Brazilian state of Santa Catarina lies to the north, Uruguay to the south, Argentina to the west and the Atlantic Ocean to the east.
Surveillance for YF in non-human primates
An epizootic is defined as a disease that appears as new cases in a given animal population over a short period of time in a defined geographical area. Yellow fever epizootics are confirmed based on laboratory evidence of YFV infection in specimens collected from affected non-human primates or mosquitos. For rapid implementation of control measures, suspected YF epizootics are classified based on epidemiologic linkage, when four or more non-human primate deaths are identified in areas with evidence of YFV circulation, 10 or more dead animals are found in bordering areas or non-human primate die-offs occur in environments similar to those with evidence of YFV circulation. Evidence of YFV circulation included probable locations of infection of confirmed human YF cases, confirmed YF epizootics or YFV detection in mosquitoes collected during case or epizootic investigations.
Passive surveillance for epizootic disease in non-human primates is conducted as previously described . Briefly, sightings of sick or dying monkeys and discovery of non-human primate carcasses were reported to the passive surveillance system through municipal or state health authorities and investigated by municipal health departments.
Active surveillance for evidence of YFV circulation included capture of forest-dwelling primates for collection of blood and sera, and collection of mosquitoes for identification and virus isolation . Active surveillance was employed following investigations of non-human primate deaths when biological specimens could not be obtained or in “silent” areas with no information about presence of YFV or antibodies in non-human primate populations.
Enhanced surveillance was conducted in areas bordering those with evidence of YFV circulation or similar environmental features. Enhanced surveillance included active case finding, immediate investigation of non-human primate deaths and expedited specimen processing. Findings of non-human primate carcasses in other municipalities triggered control vaccination of the human population within a 2 km radius for events in a rural area or 300 m in urban areas pending laboratory confirmation of the presence of YFV. During the outbreak response, YF vaccination was recommended immediately from 9 months of age in municipalities with evidence of YFV circulation (“affected areas”) and all the surrounding municipalities which have borders with municipalities with confirmed YFV circulation (“expanded areas”).
Classification of human YF cases
The suspected case definition for human YF was a patient with sudden onset of fever accompanied by jaundice or hemorrhage. Patients with recent YF vaccination were investigated for possible adverse events of vaccination, including YF vaccine-associated acute viscerotropic disease. Suspected cases with laboratory evidence of YF infection or exposure during the incubation period to affected areas without an alternative diagnosis were classified as confirmed cases. Laboratory evidence of YF infection included virus isolation , viral antigen identification , , detection of YF specific immunoglobulin M (IgM) by immunoassay  or hemagglutination inhibition tests . The diagnosis of YF was discarded in suspect cases without laboratory evidence of YF infection or exposure to affected areas, or with confirmed diagnosis of another illness.
During investigations of reported deaths of non-human primates, field teams rapidly assessed vaccination coverage among residents of surrounding areas and carried out active searches for suspected cases of YF among symptomatic individuals.
The probable place of infection for human cases was defined as an area with epidemiological evidence of YFV circulation, where the human case was exposed during the incubation period.
Data collection and analysis
For municipalities in which vaccination against YF was recommended as of July 5, 2009, we calculated the number of days from first report of deaths among non-human primates to laboratory confirmation of YFV, date of vaccine recommendation or onset of illness for confirmed human YF cases. We defined as timely vaccine recommendations within two weeks (14 days) of first reported deaths among non-human primates. We excluded one human case identified more than one year after disease occurrence during review of surveillance data.
Data on the number of YF vaccine doses administered in each municipality by month during the outbreak period were obtained from the Rio Grande do Sul state immunization program. Administrative estimates of YF vaccine coverage were obtained by dividing the cumulative number of doses administered (including doses administered prior to the outbreak from January, 2001 through October, 2008) by the total population of municipalities with YF vaccine recommendation.
Prior to the beginning of the outbreak in October, 2008, vaccination against YF was recommended in 52 municipalities, with a total population of 531,163. By June, 2009, after eight months of YFV spread, YF vaccination was recommended in 293 municipalities, with a total population of 6.9 million inhabitants (Table 1).
Of the 293 municipalities in which yellow fever vaccination was recommended by July, 2009, 67 (23%) were classified as “affected areas” (based on confirmed YFV circulation during the outbreak period) and 226 (77%) as “expanded areas” (Figure 2). Of these, 61 (21%) municipalities reported monkey deaths without laboratory evidence of YFV circulation and 165 (56%) were adjacent to municipalities with YFV circulation but had no reports of monkey deaths during the outbreak period. In 26 additional municipalities, epizootics were reported but laboratory and environmental investigations did not suggest YFV circulation and vaccination was not recommended.
(Shading corresponds to municipalities with confirmed yellow fever epizootics in non-human primates).
Between November 30, 2008 and July 5, 2009, vaccination against YF was initiated in 241 municipalities (Figure 3). Among 67 municipalities with confirmed YFV circulation, implementation of YF vaccine recommendations was considered timely in 39 (58%): YF vaccine was recommended before the outbreak in 23 municipalities (11 with vaccination since 2001) while in 16, recommendations were implemented within 2 weeks of the first report of epizootic activity. In 28 (42%) of 67 municipalities with confirmed YFV circulation, vaccine recommendations were implemented more than 2 weeks (range 15 to 138 days) after first reported epizootic activity.
Municipalities in which YF vaccination was recommended (shaded area) by timing of recommendation.
During the 9-month period, a total of 118 suspected human cases of YF were reported from 59 municipalities: 21 (18%) were confirmed based on laboratory and epidemiologic evidence, while YF was discarded in 97 (82%) without laboratory evidence of YF infection. Case-fatality among confirmed YF cases was 43% (9 of 21). None of the confirmed cases had documented history of YF vaccination. All confirmed human cases had been exposed to forested areas and, consequently, to the presence of sylvatic vectors, including Haemagogus leucocelaenus. Enhanced surveillance did not identify the presence of other mosquito vectors, including H. spegazzinii, H. janthinomys or Sabethes sp. Specimens from human cases were collected an average of 10 days (range, 2 to 17 days) after reported onset of symptoms and YFV infection was confirmed by laboratory testing from 13 to 53 days after symptom onset.
Nine municipalities were identified as probable locations of infection for 21 confirmed human YF cases. Of these, deaths of non-human primates were reported in eight (89%) municipalities 12 days to two months prior to onset of illness in persons with confirmed YF (Table 2). In two municipalities in the northwestern part of the state (each the probable location of infection for one human case) in which vaccination had been recommended since 2001, one case occurred in a recently arrived resident and one in a visitor to the area. Although in both cases family members reported being vaccinated, neither case patient was aware of YF vaccine recommendations in the area. In four other municipalities in the northwestern part of the state, YF vaccination was recommended within 7 days of the first report of deaths among non-human primates, before results of laboratory testing confirmed YFV epizootics. In two municipalities in the central part of the state (Santa Cruz do Sul and Vera Cruz), probable locations of infection for 11 human cases, vaccination began more than two months after deaths of non-human primates were first reported. Specimens collected in the municipality following initial investigations tested negative for the presence of YFV (Table 2).
By the end of February, 2009, more than 1.6 million doses of YF vaccine had been administered in municipalities in which vaccine was recommended, with a total population of 1.8 million. Rural areas were prioritized for vaccination. By July, 2009, more than 4.2 million doses had been administered, but the total population in municipalities with YF vaccine recommendation had jumped to 6.9 million, resulting in lower estimates of administrative coverage. Estimated coverage in more populous urban areas lagged behind coverage in rural areas. By the end of 2010, administrative coverage of YF vaccine in the area where vaccination was recommended was greater than 80%. Of 67 municipalities with confirmed YF epizootics during the 2008–09 outbreak, 41 (69%) reported administrative vaccination coverage of 90% or greater, versus 124 (55%) of 226 municipalities without confirmed YF epizootics during the outbreak.
Our analysis of the vaccination response to a YF outbreak in southern Brazil in 2008–2009 highlights challenges of using epizootic surveillance as an early warning system for YF in humans. Delay in detection or confirmation of YF epizootics may have resulted in late initiation of vaccination strategies in several municipalities with documented YFV transmission. Reporting of suspected epizootics and vaccination activities occurred most rapidly in areas where viral circulation had been identified during epizootic activity in 2001 and 2002, where many professionals had received training on YF surveillance. However, the rapid spread of YFV to areas previously free of the virus , where YF vaccination was not recommended, overwhelmed public health services, affecting the timeliness of the sampling and laboratory confirmation of YFV circulation. Even when specimens were obtained, laboratory confirmation by reference laboratories of the presence of YFV required a minimum of 13 days. Immunization strategies take time to reach high coverage, and vaccine-induced immunity develops over 7–14 days . Early in an outbreak, information from epizootic surveillance may be most useful to identify populations at highest risk of YFV exposure to prioritize vaccination and other prevention strategies, including personal protection.
In two municipalities that accounted for more than 50% of human cases, detection of YFV in non-human primates was delayed. Despite collection of specimens from non-human primates prior to occurrence of human cases, vaccination was not initiated until later specimens tested positive for YFV. Delayed initiation of vaccination in these municipalities where YF vaccine had not been recommended previously may have contributed to higher numbers of people infected in this area. Prevention of human YF cases requires immediate risk communication and implementation of vaccine recommendations after the first reports of epizootic activity when YF is suspected. Based on epizootic surveillance, YF vaccination was recommended in 165 municipalities in “expanded areas” without any reports of dead monkey sightings, as well as 61 municipalities in which epizootic events were not confirmed to be yellow fever. By defining outlying areas as “at risk”, authorities did not wait to confirm YFV circulation before initiating vaccination activities.
Investigation of reported monkey deaths during the outbreak provided evidence of extensive YF epizootics in non-human primates . In six months, YFV circulation in monkeys spread more than 600 km from west to east, spreading from 2 municipalities with confirmed circulation of YFV to 67 municipalities , . Prior to the epidemic, active surveillance for the presence of YFV and other arboviruses among howler monkeys (Alouatta sp.) identified no immunity to YFV in this population . However, active surveillance identified YFV-antibodies in howler monkey captured in November, 2009, several months after the outbreak period (unpublished data). Data from the investigations of epizootic activity during this outbreak provided new information about YFV transmission in susceptible howler monkey populations. Further study is needed to understand how YFV is spread between troops of howler monkeys in areas susceptible to YFV circulation and how environmental factors influence YFV occurrence and spread.
In 2011, following the epidemic, the Rio Grande do Sul state health department in coordination with the Brazilian Ministry of Health recommended YF vaccination in an additional 169 municipalities (Figure 3), leaving only 34 (7%) of 496 municipalities in the state without vaccine recommendation. The decision to extend YF vaccination to previously unaffected municipalities was based on the rapid spread of YFV circulation in 2008/2009, environmental characteristics, population movements and discussions with YF experts and scientific advisory committees. Better communication of YF recommendations to travelers are also needed; two of the human cases were probably infected with YF virus in areas in which vaccination had been recommended since 2001, yet neither was aware of vaccine recommendations.
The purpose of surveillance for YFV infection in non-human primates is to prevent YF cases and deaths among humans. In Rio Grande do Sul, surveillance in non-human primates was unable to predict the 2008–2009 outbreak or the rapid spread of YFV transmission, although it detected YFV circulation in non-human-primates in October, 2008 before human cases occurred. Also, active surveillance prior to the outbreak identified a susceptible population of non-human primates. During the outbreak, surveillance for epizootic activity allowed health authorities to monitor virus spread and informed vaccination strategies. In addition, surveillance for epizootics in non-human primates may have averted human cases by alerting the public to the risk of YF and intensifying vaccination efforts, although the number of human cases prevented through vaccination is unknown. Unfortunately, we had different levels of response according to the preparedness of municipalities and the familiarity of the various regions of the state with this type of emergency. The epidemic of 2008–2009 hit areas of the state in which we had no information on any previous occurrence of YF. Active surveillance for YFV infection in non-human primates in the state also developed capacity by training over 300 health professionals from Rio Grande do Sul and other Brazilian states, leading to improved reporting and investigation of epizootic events. Continued monitoring and evaluation of surveillance for YF in non-human primates in Brazil is essential to improve performance. Communication strategies to inform persons at risk of exposure to sylvatic yellow fever may also encourage reporting of epizootic events, to improve rapid detection and response to future YF outbreaks.
We acknowledge the important contributions of Municipal Health Departments and our colleagues from Regional Health Departments for assistance with field investigation and sample collection, and the arbovirus reference laboratories at Evandro Chagas Institute in Belém and Adolfo Lutz Institute in São Paulo. Erin Staples from the U.S. Centers for Disease Control and Prevention gave us helpful advice on the manuscript. We also thank Carlos Alberto Noll, Waldemar Pereira Vieira and Glênio Marchi Rosa. This paper was written due to the constant encouragement from Vivyanne Santiago Magalhães, who helped with a large amount of suggestions and patience.
Conceived and designed the experiments: MABA JdCC EdS DFdF LLC FJCF MAB KCV MAP RM TMSR MTS AFS FZP ZMAN APMR ZGC SLG BF. Performed the experiments: MABA JdCC EdS DFdF LLC FJCF MAB KCV MAP RM TMSR MTS ZMAN. Analyzed the data: MABA JdCC AFS FZP APMR ZGC SLG BF. Wrote the paper: MABA JdCC EdS DFdF LLC FJCF MAB KCV MAP RM TMSR MTS AFS FZP ZMAN APMR ZGC SLG BF.
- 1. Monath TP (2001) Yellow fever: an update. Lancet Infect Dis 1: 11–20. doi: 10.1016/s1473-3099(01)00016-0
- 2. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, et al. (2011) The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11: 622–632. doi: 10.1016/s1473-3099(11)70147-5
- 3. Pan American Health Organization (2005) Control of Yellow Fever: Field Guide. Washington, D.C.: PAHO. 30 p.
- 4. Soper FL (1963) The elimination of urban yellow fever in the Americas through the eradication of Aedes aegypti. Am J Public Health Nations Health 53: 7–16. doi: 10.2105/ajph.53.1.7
- 5. Soper F (1936) Jungle yellow fever. A new epidemiological entity in South America. Revista de Hygiene e Saúde Pública 10: 107–144.
- 6. Vasconcelos PF (2003) [Yellow Fever]. Rev Soc Bras Med Trop 36: 275–293. doi: 10.1590/s0037-86822003000200012
- 7. Almeida MAB, Santos E, Cardoso JC, Fonseca DF, Noll CA, et al. (2012) Yellow fever outbreak affecting Alouatta populations in southern Brazil (Rio Grande do Sul State), 2008–2009. Am J Primatol 74: 68–76. doi: 10.1002/ajp.21010
- 8. Holzmann I, Agostini I, Areta JI, Ferreyra H, Beldomenico P, et al. (2010) Impact of yellow fever outbreaks on two howler monkey species (Alouatta guariba clamitans and A. caraya) in Misiones, Argentina. Am J Primatol 72: 475–480. doi: 10.1002/ajp.20796
- 9. Pan American Health Organization (1979) Andanzas por el mundo de la salud: Memórias de Fred Lowe Soper; Duffy J, editor. Washington, D.C.: Pan American Health Organization.
- 10. Rifakis PM, Benitez JA, De-la-Paz-Pineda J, Rodriguez-Morales AJ (2006) Epizootics of yellow fever in Venezuela (2004–2005): an emerging zoonotic disease. Ann N Y Acad Sci 1081: 57–60. doi: 10.1196/annals.1373.005
- 11. Sallis ES, de Barros VL, Garmatz SL, Fighera RA, Graca DL (2003) A case of yellow fever in a brown howler (Alouatta fusca) in Southern Brazil. J Vet Diagn Invest 15: 574–576. doi: 10.1177/104063870301500611
- 12. World Health Organization (2013) Vaccines and vaccination against yellow fever: WHO Position Paper – June 2013. Weekly Epidemiological Record 88: 269–284.
- 13. World Health Organization (2010) Yellow fever fact sheet. Weekly Epidemiological Record 85: 33–36.
- 14. Torres MAN, Santos E, Almeida MAB, Cruz LL, Sperb AF (2003) Vigilância da febre amarela silvestre no Rio Grande do Sul. Epidemiological Bulletin (Rio Grande do Sul, Brazil) 6. doi: 10.5007/2175-7925.2012v25n3p217
- 15. Vasconcelos PF, Sperb AF, Monteiro HA, Torres MA, Sousa MR, et al. (2003) Isolations of yellow fever virus from Haemagogus leucocelaenus in Rio Grande do Sul State, Brazil. Trans R Soc Trop Med Hyg 97: 60–62. doi: 10.1016/s0035-9203(03)90023-x
- 16. Santos E, Almeida MAB, Fonseca DF, Vasconcelos PFC, Rodriguez SG (2006) Registro de anticorpos para o vírus Saint Louis em primata não humano no Estado do Rio Grande do Sul. Epidemiological Bulletin of the Rio Grande do Sul health department 8: 6–7.
- 17. Cardoso JC, Almeida MAB, Santos E, Fonseca DF, Sallum MAM, et al. (2010) Yellow fever virus in Haemagogus leucocelaenus and Aedes serratus mosquitoes, southern Brazil, 2008. Emerg Infect Dis 16: 1918–1924. doi: 10.3201/eid1612.100608
- 18. Brazilian Institute of Geography and Statistics 2010 Census: initial results.
- 19. Brazilian Ministry of Health (2005) Manual de vigilância de epizootias em primatas não humanos. Brasília, Brazil: National Health Foundation (FUNASA), Ministry of Health. 56 p.
- 20. Beaty B, Calisher C, Shope R (1989) Arboviruses. In: Schmidt N, Emmons R, editors. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, 6th edition. Washington, D. C. : American Public Health Association. pp. 797–855.
- 21. De Brito T, Siqueira SA, Santos RT, Nassar ES, Coimbra TL, et al. (1992) Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 188: 177–181. doi: 10.1016/s0344-0338(11)81176-3
- 22. Hall WC, Crowell TP, Watts DM, Barros VL, Kruger H, et al. (1991) Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg 45: 408–417.
- 23. Kuno G, Gomez I, Gubler DJ (1987) Detecting artificial anti-dengue IgM immune complexes using an enzyme-linked immunosorbent assay. Am J Trop Med Hyg 36: 153–159.